Equity Details
Price & Market Data
Price: $4.99
Daily Change: -$0.257 / 5.14%
Daily Range: $4.45 - $5.10
Market Cap: $1,511,608,192
Daily Volume: 16,942,412
Performance Metrics
1 Week: 6.22%
1 Month: 35.25%
3 Months: 56.65%
6 Months: 26.60%
1 Year: 140.3%
YTD: 44.74%
About AbCellera Biologics Inc. (ABCL)
Comprehensive market data and analysis for AbCellera Biologics Inc. (ABCL). Current price: 4.99, daily change: -$0.257 / 5.14%. Market cap: 1,511,608,192. View detailed YTD, 1-week, and 1-month performance.
Company Details
Employees: 562
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.